GDS Wealth Management Trims Holdings in AstraZeneca PLC (NASDAQ:AZN)

GDS Wealth Management trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 4,973 shares of the company’s stock after selling 736 shares during the period. GDS Wealth Management’s holdings in AstraZeneca were worth $326,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AZN. AQR Capital Management LLC grew its position in AstraZeneca by 112.4% during the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock worth $1,067,000 after buying an additional 7,241 shares in the last quarter. Centaurus Financial Inc. purchased a new position in AstraZeneca during the second quarter worth about $182,000. GAMMA Investing LLC grew its position in AstraZeneca by 19.5% during the third quarter. GAMMA Investing LLC now owns 5,433 shares of the company’s stock worth $423,000 after buying an additional 887 shares in the last quarter. Fulton Bank N.A. grew its position in AstraZeneca by 2.3% during the third quarter. Fulton Bank N.A. now owns 9,329 shares of the company’s stock worth $727,000 after buying an additional 211 shares in the last quarter. Finally, Aprio Wealth Management LLC grew its position in AstraZeneca by 20.0% during the third quarter. Aprio Wealth Management LLC now owns 5,162 shares of the company’s stock worth $402,000 after buying an additional 860 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

AstraZeneca Stock Down 1.3 %

AZN stock opened at $69.86 on Tuesday. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68. The business’s 50 day moving average price is $67.08 and its two-hundred day moving average price is $73.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The company has a market capitalization of $216.64 billion, a price-to-earnings ratio of 33.43, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.87 EPS. As a group, analysts forecast that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on AZN shares. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.